Gastric Cancer
📧 Sign up to get email alerts when something new happens for Gastric Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-01-05FDA Approved: OXALIPLATIN — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for oxaliplatin submitted by Sagent Pharmaceuticals.
-
FDA approval · 2023-12-11FDA Approved: OXALIPLATIN — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
The FDA approved a supplemental application for the generic oxaliplatin product submitted by Qilu Pharmaceutical Co., Ltd. under ANDA204368.
-
FDA approval · 2023-10-02FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)
FDA approved a supplemental Biologics License Application for OGIVRI (trastuzumab-dkst) from Biocon Biologics Inc. The biosimilar is intende…
-
FDA approval · 2023-09-19FDA Approved: DOCETAXEL — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal's supplemental application to manufacture and market a generic docetaxel, enabling its supply for cancer treatment i…
-
FDA approval · 2023-09-15FDA Approved: DOCETAXEL — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for docetaxel from Gland Pharma Limited under an ANDA for the generic product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-11-22FDA Approved: DOCIVYX — Original Application (Avyxa Pharma, LLC)
FDA approves DOCIVYX (docetaxel) under an original NDA submitted by Avyxa Pharma, LLC.
-
FDA approval · 2022-10-18FDA Approved: FLUOROURACIL — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved a supplemental application for fluorouracil submitted by Taro Pharmaceuticals U.S.A., Inc., approving changes to the product’s …
-
FDA approval · 2022-09-14FDA Approved: FLUOROURACIL — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for fluorouracil submitted by BluePoint Laboratories, indicating approval of an ANDA supplement. Thi…
-
FDA approval · 2022-08-11FDA Approved: ENHERTU — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for ENHERTU (fam-trastuzumab deruxtecan-nxki) filed by Daiichi Sankyo, Inc.
-
FDA approval · 2022-08-05FDA Approved: ENHERTU — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for ENHERTU (fam-trastuzumab deruxtecan-nxki) from Daiichi Sankyo Inc. to update labeling and/or add…
-
FDA approval · 2022-03-08FDA Approved: OXALIPLATIN — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for oxaliplatin by Mylan Institutional LLC, finalizing changes to the generic product's labeling und…
-
FDA approval · 2021-07-01FDA Approved: DOCETAXEL — Original Application (Gland Pharma Limited)
FDA approves Gland Pharma Limited's generic docetaxel as an Original Application, adding a new generic option for cancer chemotherapy.
-
FDA approval · 2021-01-14FDA Approved: DOCETAXEL — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s original application for generic docetaxel. Docetaxel is a chemotherapy agent used to treat mu…
-
FDA approval · 2020-09-10FDA Approved: DOCETAXEL — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for a generic docetaxel product (docetaxel anhydrous) from Mylan Institutional LLC.
-
FDA approval · 2020-06-29FDA Approved: PHESGO — Original Application (Genentech, Inc.)
FDA approved PHESGO (PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF) from Genentech under an Original Application; a fixed-dose subcutaneou…
-
FDA approval · 2020-01-24FDA Approved: TRAZIMERA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Pfizer's supplemental Biologics License Application for TRAZIMERA (trastuzumab-qyyP), a biosimilar to trastuzumab.
-
FDA approval · 2019-10-25FDA Approved: KANJINTI — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for KANJINTI (trastuzumab-anns) submitted by Amgen, Inc. The action represents a regulatory approval…
-
FDA approval · 2019-10-10FDA Approved: CAPECITABINE 150MG — Supplemental Application (Armas Pharmaceuticals Inc.)
The FDA approved a supplemental application to add a 150 mg strength of capecitabine, manufactured by Armas Pharmaceuticals Inc., expanding …
-
FDA approval · 2019-10-09FDA Approved: CAPECITABINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for Capecitabine (CAPECITABINE) from Ascend Laboratories, LLC under ANDA207652.
-
FDA approval · 2019-06-28FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)
FDA approved a supplemental Biologics License Application for OGIVRI (trastuzumab-dkst) from Biocon Biologics Inc., updating its labeling/pe…
-
FDA approval · 2019-06-21FDA Approved: CAPECITABINE — Original Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries' original application for Capecitabine, granting a generic version of the cancer drug Capecit…
-
FDA approval · 2019-06-13FDA Approved: KANJINTI — Original Application (Amgen, Inc)
FDA approves KANJINTI (trastuzumab-anns) from Amgen as a biosimilar to trastuzumab. It is approved for HER2-overexpressing breast cancer and…
-
FDA approval · 2019-04-17FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)
The FDA approved Biocon Biologics' supplemental application for OGIVRI (trastuzumab-dkst), a trastuzumab biosimilar.
-
FDA approval · 2019-04-01FDA Approved: DOCETAXEL — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for Docetaxel from Dr. Reddy's Laboratories Inc., authorizing the generic product under the approved…
-
FDA approval · 2019-03-13FDA Approved: DOCETAXEL ANHYDROUS — Supplemental Application (Meitheal Pharmaceuticals Inc)
The FDA approved a supplemental application from Meitheal Pharmaceuticals to market docetaxel anhydrous as a generic chemotherapy drug.